Broken RECORD: New Themes, Same Old Story for Avandia
Executive Summary
Count Rep. Rosa DeLauro among those who remain highly critical of the Food and Drug Administration's handling of GlaxoSmithKline's type 2 diabetes drug Avandia (rosiglitazone). The Connecticut Democrat, whose chairmanship of the House Agriculture Appropriations Subcommittee gives her something like life-and-death authority over FDA, made her feelings on the subject abundantly clear during an Institute of Medicine workshop on regulatory science February 26